Get the latest tech news

There’s New Hope for an HIV Vaccine

A trial vaccine has succeeded in generating low levels of antibodies needed to target HIV. It’s a first but much-needed step toward preventing infection.

An experimental vaccine developed at Duke University triggered an elusive type of broadly neutralizing antibody in a small group of people enrolled in a 2019 clinical trial. A few years ago, a team from Scripps Research and the International AIDS Vaccine Initiative (IAVI) showed that it was possible to stimulate the precursor cells needed to make these rare antibodies in people. “This is a scientific feat and gives the field great hope that one can construct an HIV vaccine regimen that directs the immune response along a path that is required for protection,” Gray says.

Get the Android app